Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study

Powles, T. B.Chistyakov, V.Beliakouski, V.Semenov, A.Everaert, E.Baranau, Y.Moreno, V.Valderrama, B. PerezVano, Y.Del Conte, G.Loriot, Y.Kang, T. W.Tammaro, M.O'Hagan, A.Hosseini, M.Triantos, S.Chhabra, H.Santiago-Walker, A.Siefker-Radtke, A. O.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/27230enErdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE studyconference outputopen access10.1016/j.annonc.2021.08.21031569-8041https://doi.org/10.1016/j.annonc.2021.08.2103700527703502